Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr virus

ACS Chemical Biology

Volumn 9, Issue 3, 2014, Pages 785-795

  Tikhmyanova, Nadezhda ^a   Schultz, David C ^a   Lee, Theresa ^a   Salvino, Joseph M ^b   Lieberman, Paul M ^a  

^a WISTAR INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; GANCICLOVIR; HISTONE DEACETYLASE INHIBITOR; PHORBOL ESTER; TETRAHYDROCARBOLINE DERIVATIVE; UNCLASSIFIED DRUG; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; IMMEDIATE EARLY PROTEIN; MOLECULAR LIBRARY; TRANSACTIVATOR PROTEIN;

ARTICLE; CELL KILLING; CELL LINE; CELL TYPE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HERPES VIRUS; NONHUMAN; PRIORITY JOURNAL; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; MOLECULAR LIBRARY; PHARMACOLOGY; PHYSIOLOGY; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

CELL LINE; CELL SURVIVAL; HERPESVIRUS 4, HUMAN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMEDIATE-EARLY PROTEINS; MOLECULAR STRUCTURE; SMALL MOLECULE LIBRARIES; TRANS-ACTIVATORS; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84896929392     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4006326     Document Type: Article

References (39)

1. Rickinson, A. B. and Kieff, E. (2007) Epstein-Barr Virus, 5 th ed., Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
2. Kieff, E. (2007) Epstein-Barr Virus and Its Replication, 5 th ed., Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.
3. Thorley-Lawson, D. A. (2005) EBV the prototypical human tumor virus - just how bad is it' J. Allergy Clin. Immunol. 116, 251-261 quiz 262
4. Klein, E., Kis, L. L., and Klein, G. (2007) Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions Oncogene 26, 1297-1305
5. Raab-Traub, N. (2002) Epstein-Barr virus in the pathogenesis of NPC Sem. Cancer Biol. 12, 431-441
6. Fukayama, M. and Ushiku, T. (2011) Epstein-Barr virus-associated gastric carcinoma Pathol., Res. Pract. 207, 529-537
7. Loren, A. W., Porter, D. L., Stadtmauer, E. A., and Tsai, D. E. (2003) Post-transplant lymphoproliferative disorder: a review Bone Marrow Transplantation 31, 145-155
8. Gottschalk, S., Rooney, C. M., and Heslop, H. E. (2004) Post-transplant lymphoproliferative Disorders Annu. Rev. Med. 56, 29-44
9. Hamilton-Dutoit, S. J., Rea, D., Raphael, M., Sandvej, K., Delecluse, H. J., Gisselbrecht, C., Marelle, L., van Krieken, H. J., and Pallesen, G. (1993) Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency Am. J. Pathol. 143, 1072-1085
10. MacMahon, E. M., Glass, J. D., Hayward, S. D., Mann, R. B., Becker, P. S., Charache, P., McArthur, J. C., and Ambinder, R. F. (1991) Epstein-Barr virus in AIDS-related primary central nervous system lymphoma Lancet 338, 969-973
11. Young, L. S. and Rickinson, A. B. (2004) Epstein-Barr virus: 40 years on Nat. Rev. Cancer 4, 757-768
12. Gutierrez, M. I., Judde, J. G., Magrath, I. T., and Bhatia, K. G. (1996) Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia Cancer Res. 56, 969-972
13. Kenney, S., Ge, J. Q., Westphal, E. M., and Olsen, J. (1998) Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors Human Gene Therapy 9, 1131-1141
14. Moore, S. M., Cannon, J. S., Tanhehco, Y. C., Hamzeh, F. M., and Ambinder, R. F. (2001) Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues Antimicrob. Agents Chemother. 45, 2082-2091
15. Perrine, S. P., Hermine, O., Small, T., Suarez, F., O'Reilly, R., Boulad, F., Fingeroth, J., Askin, M., Levy, A., Mentzer, S. J., Di Nicola, M., Gianni, A. M., Klein, C., Horwitz, S., and Faller, D. V. (2007) A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies Blood 109, 2571-2578
16. Ghosh, S. K., Perrine, S. P., Williams, R. M., and Faller, D. V. (2012) Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents Blood 119, 1008-1017
17. Shirley, C. M., Chen, J., Shamay, M., Li, H., Zahnow, C. A., Hayward, S. D., and Ambinder, R. F. (2011) Bortezomib induction of C/EBPbeta mediates Epstein-Barr virus lytic activation in Burkitt lymphoma Blood 117, 6297-6303
18. Yates, J. L., Warren, N., and Sugden, B. (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells Nature 313, 812-815
19. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screening 4, 67-73
20. Thorne, N., Shen, M., Lea, W. A., Simeonov, A., Lovell, S., Auld, D. S., and Inglese, J. (2012) Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter Chem. Biol. 19, 1060-1072
21. Countryman, J., Gradoville, L., Bhaduri-McIntosh, S., Ye, J., Heston, L., Himmelfarb, S., Shedd, D., and Miller, G. (2009) Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus J. Virol. 83, 10694-10709
22. Miller, G., El-Guindy, A., Countryman, J., Ye, J., and Gradoville, L. (2007) Lytic cycle switches of oncogenic human gammaherpesviruses(1) Adv. Cancer Res. 97, 81-109
23. Miller, G., El-Guindy, A., Countryman, J., Ye, J., and Gradoville, L. (2007) Lytic cycle switches of oncogenic human gammaherpesviruses Adv. Cancer Res. 97, 81-109
24. Daigle, D., Gradoville, L., Tuck, D., Schulz, V., Wang'ondu, R., Ye, J., Gorres, K., and Miller, G. (2011) Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle J. Virol. 85, 5628-5643
25. Daigle, D., Megyola, C., El-Guindy, A., Gradoville, L., Tuck, D., Miller, G., and Bhaduri-McIntosh, S. (2010) Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors J. Virol. 84, 993-1004
26. Marks, P. A., Richon, V. M., Kelly, W. K., Chiao, J. H., and Miller, T. (2004) Histone deacetylase inhibitors: development as cancer therapy Novartis Foundation symposium 259, 269-281 discussion 281-268
27. Nakagawa, Y. (2012) Artificial analogs of naturally occurring tumor promoters as biochemical tools and therapeutic leads Biosci. Biotechnol. Biochem. 76, 1262-1274
28. Gao, X., Ikuta, K., Tajima, M., and Sairenji, T. (2001) 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase Virology 286, 91-99
29. Griner, E. M. and Kazanietz, M. G. (2007) Protein kinase C and other diacylglycerol effectors in cancer Nat. Rev. Cancer 7, 281-294
30. Amon, W. and Farrell, P. J. (2005) Reactivation of Epstein-Barr virus from latency Rev. Med. Virol. 15, 149-156
31. Lai, I. Y., Farrell, P. J., and Kellam, P. (2011) X-box binding protein 1 induces the expression of the lytic cycle transactivator of Kaposi's sarcoma-associated herpesvirus but not Epstein-Barr virus in co-infected primary effusion lymphoma J. Gen. Virol. 92, 421-431
32. Davies, M. L., Xu, S., Lyons-Weiler, J., Rosendorff, A., Webber, S. A., Wasil, L. R., Metes, D., and Rowe, D. T. (2010) Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines Virology 400, 53-67
33. Pasternak, A., Feng, Z., de Jesus, R., Ye, Z., He, S., Dobbelaar, P., Bradley, S. A., Chicchi, G. G., Kwei-Lan Tsao, D. T., Eiermann, G. J., Li, C., Feng, Y., Wu, M., Shao, Q., Zhang, B. B., Nargund, R., Mills, S. G., Howard, A. D., Yang, L., and Zhou., Y.-P. (2012) Stimulation of glucose-dependent insulin secretion by a potent, selective sst3 antagonist ACS Med. Chem. Lett. 3, 289-293
34. Daugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A. C., Coste, H., Kirilovsky, J., Hyafil, F., and Labaudiniere, R. (2003) The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1 H -imidazo[1',5':1,6]pyrido[3,4- b ]indole-1,3(2 H)-dione analogues J. Med. Chem. 46, 4525-4532
35. Tempera, I., Wiedmer, A., Dheekollu, J., and Lieberman, P. M. (2010) CTCF prevents the epigenetic drift of EBV latency promoter Qp PLoS Pathog. 6 e1001048
36. Deng, Z., Chen, C.-J., Zerby, D., Delecluse, H.-J., and Lieberman, P. M. (2001) Identification of acidic and aromatic residues in the Zta activation omain essential for Epstein-Barr virus reactivation J. Virol. 75, 10334-10347
37. Ragoczy, T. and Miller, G. (2001) Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites J. Virol. 75, 5240-5251
38. Thompson, S., Messick, T., Schultz, D. C., Reichman, M., and Lieberman, P. M. (2010) Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1 J. Biomol. Screening 15, 1107-1115
39. Auld, D. S., Southall, N. T., Jadhav, A., Johnson, R. L., Diller, D. J., Simeonov, A., Austin, C. P., and Inglese, J. (2008) Characterization of chemical libraries for luciferase inhibitory activity J. Med. Chem. 51, 2372-2386